Biomarkers of hypoxia evaluation with molecular and 64copper (II) diacetylbis (N4)methylthiosemicarbazone (CuATSM) positron emission tomography/computed tomography (PET/CT) imaging techniques in head and neck squamous cell carcinomas (BoHEMIaN study)

Guy's and St Thomas' NHS Foundation Trust (UK)0 个研究点目标入组 40 人开始时间: 2012年10月11日最近更新: 2017年2月20日

适应症

试验速览

暂无简介。

•1. Patients with stage III-IV histologically proven HPV negative oropharyngeal squamous cell carcinoma to be treated with radical concomitant chemotherapy and radiotherapy
•2. Patients have consented to their original biospy being stored in the tissue bank at GSTFT
•3. Age > 18 years
•4. ECOG Performance Status 5. Life expectancy > 12 weeks
•6. Adequate organ function and absence of other major concomitant illness, allowing the patient to tolerate the delivery of the radiotracer
•7. Patients must be able to provide written and voluntary informed consent
•8. All women of childbearing age must have a negative serum or urine pregnancy test documented within 72 hours prior to study enrollment
•9. Male and female participants

•1. Patients with impaired renal function (serum creatinine > 200)
•2. Patients with severely impaired liver function
•3. Serious intercurrent conditions or other nonmalignant illnesses that are uncontrolled or whose control may be affected by participation in this study
•4. Any patient who has urinary or faecal incontinence
•5. Previous history of cancer other than skin basal cell carcinoma
•6. ECOG Performance Status >/= 3
•7. Pregnant or breastfeeding women

发起方

Guy's and St Thomas' NHS Foundation Trust (UK)